Investigational drug · Phase 2
Macupatide
Also called: LY3532226
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight, Diabetes Mellitus, Type 2.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "Macupatide"
First trial start
2023
Nov 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Macupatide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
- Diabetes Mellitus, Type 2
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Macupatide" as an intervention, largest first.
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06143956 · 1,481 participants (planned) · Start Nov 17, 2023 · Primary completion Sep 2027
Drug: LY3305677; LY3841136 and 5 more · For: Obesity; Overweight
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 57 sites in all
- A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07589608 · 400 participants (planned) · Start May 15, 2026 · Primary completion Sep 2027
Drug: Macupatide; Eloralintide and 1 more · For: Overweight; Obesity
Sites: Chandler, Arizona; Scottsdale, Arizona; Tucson, Arizona · 40 sites in all
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07215559 · 200 participants (planned) · Start Oct 16, 2025 · Primary completion Mar 2027
Drug: Macupatide; Eloralintide and 2 more · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 42 sites in all
- A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07765511 · 60 participants (planned) · Start Oct 2026 · Primary completion Jun 2027
Drug: Macupatide; Eloralintide and 1 more · For: Obesity; Overweight
Sites: Fukuoka, Japan; Sumida-ku, Japan; Toshima City, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.
Heise T, Zijlstra E, Mari A, et al. · Diabetes Obes Metab 2026
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.